Insider

Cardinal Health extends its distribution agreement with CVS Health through 2032

On Oct. 1, 2026, Cardinal Health signed a binding letter of intent to extend its pharmaceutical distribution agreement with CVS Health to June 30, 2032, while reaffirming its fiscal 2027 non‑GAAP earnings per share (EPS) outlook of $12.40‑$12.60.

Verified against 3 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
white wooden desk on hallway inside building
Photo by Brandon Holmes on Unsplash

Key points

  • Cardinal Health, Inc. announced the signing of a binding letter of intent that extends its existing pharmaceutical distribution agreement with CVS Health to June 30, 2032.
  • The deal continues the current scope of distribution services under unchanged terms, preserving existing pricing and procedures through the end of June 2032.
  • In fiscal 2026, the company reported strong execution and broad‑based performance, and noted active board oversight of growth priorities, investments and capital management.

What happened

Cardinal Health, Inc. announced the signing of a binding letter of intent that extends its existing pharmaceutical distribution agreement with CVS Health to June 30, 2032.

Deal terms

The deal continues the current scope of distribution services under unchanged terms, preserving existing pricing and procedures through the end of June 2032.

Context

In fiscal 2026, the company reported strong execution and broad‑based performance, and noted active board oversight of growth priorities, investments and capital management.

What to watch

Investors should watch for the signing of a final agreement with CVS Health and for fiscal 2027 earnings per share (EPS) results to see if the company meets the reaffirmed $12.40‑$12.60 forecast.

Original sources

  1. 8-K filing, October 1, 2026October 1, 2026SHA-256 of our archived copy 8a65adfb728a…
  2. 8-K EX-99.1 filing, October 1, 2026October 1, 2026SHA-256 of our archived copy f37e37875636…
  3. DEF 14A filing, September 21, 2026September 21, 2026SHA-256 of our archived copy 5a35494598a5…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards